会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES
    • 1H-4(5) - 取代的咪唑衍生物
    • WO1996038142A1
    • 1996-12-05
    • PCT/US1996007873
    • 1996-05-29
    • GLIATECH, INC.PHILLIPS, James, G.TEDFORD, Clark, E.CHATURVEDI, Nishith, C.
    • GLIATECH, INC.
    • A61K31/415
    • C07D233/56A61K31/417A61K31/4174A61K31/4178C07D233/64C07D403/12C07D405/12
    • The present invention provides, in its principal aspect, compounds of general formula (1.0) or a pharmaceutically acceptable salt or hydrate thereof, wherein: where A is -NHCO-, -N(CH3)-CO-, -NHCH2-, -N(CH3)-CH2-, -CH=CH-, -COCH2-, -CH2CH2-, -CH(OH)CH2-, or -CC-; X is H, CH3, NH2, NH(CH3), N(CH3)2, OH, OCH3, or SH; R2 is hydrogen or a methyl or ethyl group; R3 is hydrogen or a methyl or ethyl group; n is 0, 1, 2, 3, 4, 5, or 6; and R1 is selected from the group consisting of (a) C3 to C8 cycloalkyl; (b) phenyl or substituted phenyl; (d) heterocyclic; (e) decahydronaphthalene and (f) octahydroindene; or R1 and X may be taken together to denote a 5,6 or 6,6 saturated bicyclic ring structure when X is NH, O, or S. The individual stereoisomers of compounds of structural formula (1.0) above, as well as mixtures thereof, are also contemplated as falling within the scope of the present invention. The compounds of the present invention have H3 histamine receptor antagonist activity. This invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with an effective amount of a compound of formula 1.0. The present invention also provides a method of treating conditions in which antagonism of histamine H3 receptors may be of therapeutic importance.
    • 本发明在其主要方面提供了通式(1.0)的化合物或其药学上可接受的盐或水合物,其中:A是-NHCO - , - N(CH 3)-CO - , - NHCH 2 - , - N (CH 3)-CH 2 - , - CH = CH - , - COCH 2 - , - CH 2 CH 2 - , - CH(OH)CH 2 - 或-CC-; X是H,CH 3,NH 2,NH(CH 3),N(CH 3)2,OH,OCH 3或SH; R2是氢或甲基或乙基; R3是氢或甲基或乙基; n是0,1,2,3,4,5或6; 并且R 1选自(a)C 3至C 8环烷基; (b)苯基或取代的苯基; (d)杂环; (e)十氢萘和(f)八氢茚; 或者当X是NH,O或S时,R 1和X可以一起表示5,6或6,6饱和的双环结构。上述结构式(1.0)化合物的各个立体异构体以及它们的混合物 也被认为落入本发明的范围内。 本发明化合物具有H3组胺受体拮抗剂活性。 本发明还提供药物组合物,其包含药学上可接受的载体与有效量的式1.0化合物的组合。 本发明还提供了治疗组胺H 3受体的拮抗作用具有治疗意义的病症的方法。